Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.

Breast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demons...

Full description

Bibliographic Details
Main Authors: Chhanda Bose, Sanjay Awasthi, Rajendra Sharma, Helen Beneš, Martin Hauer-Jensen, Marjan Boerma, Sharda P Singh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5843244?pdf=render
id doaj-7e723c869748445d875360ff291d3f23
record_format Article
spelling doaj-7e723c869748445d875360ff291d3f232020-11-24T21:46:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019391810.1371/journal.pone.0193918Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.Chhanda BoseSanjay AwasthiRajendra SharmaHelen BenešMartin Hauer-JensenMarjan BoermaSharda P SinghBreast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demonstrated in a mouse model that sulforaphane (SFN), an isothiocyanate isolated from cruciferous vegetables, protects the heart from DOX-induced toxicity and damage. However, the effects of SFN on the chemotherapeutic efficacy of DOX in breast cancer are not known. Present studies were designed to investigate whether SFN alters the effects of DOX on breast cancer regression while also acting as a cardioprotective agent. Studies on rat neonatal cardiomyocytes and multiple rat and human breast cancer cell lines revealed that SFN protects cardiac cells but not cancer cells from DOX toxicity. Results of studies in a rat orthotopic breast cancer model indicated that SFN enhanced the efficacy of DOX in regression of tumor growth, and that the DOX dosage required to treat the tumor could be reduced when SFN was administered concomitantly. Additionally, SFN enhanced mitochondrial respiration in the hearts of DOX-treated rats and reduced cardiac oxidative stress caused by DOX, as evidenced by the inhibition of lipid peroxidation, the activation of NF-E2-related factor 2 (Nrf2) and associated antioxidant enzymes. These studies indicate that SFN not only acts synergistically with DOX in cancer regression, but also protects the heart from DOX toxicity through Nrf2 activation and protection of mitochondrial integrity and functions.http://europepmc.org/articles/PMC5843244?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Chhanda Bose
Sanjay Awasthi
Rajendra Sharma
Helen Beneš
Martin Hauer-Jensen
Marjan Boerma
Sharda P Singh
spellingShingle Chhanda Bose
Sanjay Awasthi
Rajendra Sharma
Helen Beneš
Martin Hauer-Jensen
Marjan Boerma
Sharda P Singh
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
PLoS ONE
author_facet Chhanda Bose
Sanjay Awasthi
Rajendra Sharma
Helen Beneš
Martin Hauer-Jensen
Marjan Boerma
Sharda P Singh
author_sort Chhanda Bose
title Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
title_short Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
title_full Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
title_fullStr Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
title_full_unstemmed Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
title_sort sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Breast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demonstrated in a mouse model that sulforaphane (SFN), an isothiocyanate isolated from cruciferous vegetables, protects the heart from DOX-induced toxicity and damage. However, the effects of SFN on the chemotherapeutic efficacy of DOX in breast cancer are not known. Present studies were designed to investigate whether SFN alters the effects of DOX on breast cancer regression while also acting as a cardioprotective agent. Studies on rat neonatal cardiomyocytes and multiple rat and human breast cancer cell lines revealed that SFN protects cardiac cells but not cancer cells from DOX toxicity. Results of studies in a rat orthotopic breast cancer model indicated that SFN enhanced the efficacy of DOX in regression of tumor growth, and that the DOX dosage required to treat the tumor could be reduced when SFN was administered concomitantly. Additionally, SFN enhanced mitochondrial respiration in the hearts of DOX-treated rats and reduced cardiac oxidative stress caused by DOX, as evidenced by the inhibition of lipid peroxidation, the activation of NF-E2-related factor 2 (Nrf2) and associated antioxidant enzymes. These studies indicate that SFN not only acts synergistically with DOX in cancer regression, but also protects the heart from DOX toxicity through Nrf2 activation and protection of mitochondrial integrity and functions.
url http://europepmc.org/articles/PMC5843244?pdf=render
work_keys_str_mv AT chhandabose sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
AT sanjayawasthi sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
AT rajendrasharma sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
AT helenbenes sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
AT martinhauerjensen sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
AT marjanboerma sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
AT shardapsingh sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel
_version_ 1725900407521148928